TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $8.10 million. The enterprise value is $5.26 million.

Market Cap	8.10M
Enterprise Value	5.26M

Important Dates

The last earnings date was Friday, November 14, 2025, after market close.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 916,962 shares outstanding.

Current Share Class	916,962
Shares Outstanding	916,962
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	0.14%
Owned by Institutions (%)	6.66%
Float	832,419

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	5.16
P/TBV Ratio	5.68
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.60

Current Ratio	1.60
Quick Ratio	1.02
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,156.07

Financial Efficiency

Return on equity (ROE) is -1,763.01% and return on invested capital (ROIC) is -659.54%.

Return on Equity (ROE)	-1,763.01%
Return on Assets (ROA)	-232.54%
Return on Invested Capital (ROIC)	-659.54%
Return on Capital Employed (ROCE)	-754.63%
Revenue Per Employee	n/a
Profits Per Employee	-$3.88M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.61% in the last 52 weeks. The beta is 1.54, so RNAZ's price volatility has been higher than the market average.

Beta (5Y)	1.54
52-Week Price Change	-90.61%
50-Day Moving Average	8.52
200-Day Moving Average	9.90
Relative Strength Index (RSI)	57.99
Average Volume (20 Days)	136,251

Short Selling Information

The latest short interest is 59,476, so 6.49% of the outstanding shares have been sold short.

Short Interest	59,476
Short Previous Month	41,544
Short % of Shares Out	6.49%
Short % of Float	7.14%
Short Ratio (days to cover)	2.29

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-17.05M
Pretax Income	-27.13M
Net Income	-27.13M
EBITDA	-17.00M
EBIT	-17.05M
Earnings Per Share (EPS)	-$58.12

Balance Sheet

The company has $2.84 million in cash and n/a in debt, with a net cash position of $2.84 million or $3.09 per share.

Cash & Cash Equivalents	2.84M
Total Debt	n/a
Net Cash	2.84M
Net Cash Per Share	$3.09
Equity (Book Value)	1.43M
Book Value Per Share	1.71
Working Capital	1.78M

Cash Flow

In the last 12 months, operating cash flow was -$14.52 million and capital expenditures -$500, giving a free cash flow of -$14.52 million.

Operating Cash Flow	-14.52M
Capital Expenditures	-500
Free Cash Flow	-14.52M
FCF Per Share	-$15.84

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-335.12%
FCF Yield	-179.34%

Analyst Forecast

The average price target for RNAZ is $280.00, which is 3,071.01% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$280.00
Price Target Difference	3,071.01%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2025. It was a reverse split with a ratio of 1:28.

Last Split Date	May 15, 2025
Split Type	Reverse
Split Ratio	1:28

Scores

Altman Z-Score	n/a
Piotroski F-Score	2